Related Experiment Video
Updated: Jul 30, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Blue toe syndrome: treatment with percutaneous atherectomy
B L Dolmatch1, K S Rholl, L B Moskowitz
1Miami Vascular Institute, Baptist Hospital, FL 33176.
Insights
Percutaneous atherectomy effectively treats blue toe syndrome by removing emboli from superficial femoral artery lesions. This minimally invasive procedure resolves digital ischemia without surgery, offering histologic insights into embolic sources.
Area of Science:
- Vascular Surgery
- Interventional Cardiology
- Dermatology
Background:
- Blue toe syndrome (BTS) is characterized by digital ischemia despite palpable pedal pulses.
- It results from microembolization to distal vessels from a proximal arterial source.
- Superficial femoral artery (SFA) lesions are a common cause of embologenic BTS.
Purpose of the Study:
- To evaluate the efficacy of percutaneous transluminal atherectomy (PTA) in treating embologenic SFA lesions in patients with BTS.
- To assess the safety and outcomes of PTA in this patient population.
- To investigate the histological composition of embolic material from SFA lesions.
Main Methods:
- Seven patients with BTS underwent PTA for SFA stenosis.
- Atherectomy devices were used to remove embologenic material.
- Clinical outcomes, including resolution of ischemia and need for surgery, were monitored.
- Histological analysis of atherectomy specimens was performed.
Main Results:
- All seven patients experienced prompt healing of ischemic toes post-PTA.
- No patient required surgical revascularization or amputation.
- One patient had recurrent stenosis treated successfully with a larger atherectomy device.
- Histology revealed fibrin-platelet aggregates and thrombus as primary embolic sources, with some cholesterol atheroma.
Conclusions:
- Percutaneous atherectomy is an effective and safe treatment for embologenic SFA stenoses causing blue toe syndrome.
- PTA offers nonsurgical removal of embolic material and provides diagnostic histological information.
- This approach avoids surgical intervention and amputation in selected BTS patients.
Abstract:
"Blue toe syndrome" refers to digital ischemia of the foot in the presence of palpable or Doppler audible pedal pulses. This clinical syndrome is caused by microembolization to small vessels from a proximal source. The use of percutaneous transluminal atherectomy is described in the treatment of embologenic superficial femoral artery lesions in seven patients. All seven had prompt healing of the ischemic toes, and none required surgical revascularization or amputation. One patient developed a recurrent stenosis at the atherectomy site and had a second episode of digital ischemia, which was treated by means of atherectomy with a larger device. Histologic study of atherectomy specimens suggests that emboli arise from adherent fibrinoplatelet aggregates or thrombus and less often from cholesterol-rich atheromatous plaque. Although either percutaneous transluminal angioplasty or atherectomy can be used to treat the underlying stenosis, percutaneous atherectomy offers the advantage of nonsurgical removal of embologenic material and provides material for histologic study. Percutaneous atherectomy is an effective method of treating embologenic superficial femoral stenoses in patients with ipsilateral blue toe syndrome.
More Related Videos
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome IV: Interprofessional Care
Angina IV: Management
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care

